vs
Side-by-side financial comparison of Old Dominion (ODFL) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.3B vs $1.3B, roughly 1.7× Old Dominion). Zoetis runs the higher net margin — 26.6% vs 17.9%, a 8.7% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (2.9% vs -2.9%). Over the past eight quarters, Zoetis's revenue compounded faster (-2.1% CAGR vs -5.6%).
Old Dominion Freight Line, Inc. (ODFL) is an American regional, inter-regional and national less than truckload shipping (LTL) company. In addition to its core LTL services, the company offers expedited, logistics and household moving services.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
ODFL vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $2.3B |
| Net Profit | $238.3M | $601.0M |
| Gross Margin | — | 71.7% |
| Operating Margin | 23.8% | — |
| Net Margin | 17.9% | 26.6% |
| Revenue YoY | -2.9% | 2.9% |
| Net Profit YoY | -6.4% | -0.2% |
| EPS (diluted) | $1.14 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.3B | $2.3B | ||
| Q4 25 | $1.3B | $2.4B | ||
| Q3 25 | $1.4B | $2.4B | ||
| Q2 25 | $1.4B | $2.5B | ||
| Q1 25 | $1.4B | $2.2B | ||
| Q4 24 | $1.4B | $2.3B | ||
| Q3 24 | $1.5B | $2.4B | ||
| Q2 24 | $1.5B | $2.4B |
| Q1 26 | $238.3M | $601.0M | ||
| Q4 25 | $229.5M | $603.0M | ||
| Q3 25 | $270.9M | $721.0M | ||
| Q2 25 | $268.6M | $718.0M | ||
| Q1 25 | $254.7M | $631.0M | ||
| Q4 24 | $263.1M | $581.0M | ||
| Q3 24 | $308.6M | $682.0M | ||
| Q2 24 | $322.0M | $624.0M |
| Q1 26 | — | 71.7% | ||
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% |
| Q1 26 | 23.8% | — | ||
| Q4 25 | 23.3% | 31.9% | ||
| Q3 25 | 25.7% | 37.0% | ||
| Q2 25 | 25.4% | 36.7% | ||
| Q1 25 | 24.6% | 36.5% | ||
| Q4 24 | 24.1% | 31.6% | ||
| Q3 24 | 27.3% | 36.6% | ||
| Q2 24 | 28.1% | 33.0% |
| Q1 26 | 17.9% | 26.6% | ||
| Q4 25 | 17.6% | 25.3% | ||
| Q3 25 | 19.3% | 30.0% | ||
| Q2 25 | 19.1% | 29.2% | ||
| Q1 25 | 18.5% | 28.4% | ||
| Q4 24 | 19.0% | 25.1% | ||
| Q3 24 | 21.0% | 28.6% | ||
| Q2 24 | 21.5% | 26.4% |
| Q1 26 | $1.14 | $1.42 | ||
| Q4 25 | $1.10 | $1.37 | ||
| Q3 25 | $1.28 | $1.63 | ||
| Q2 25 | $1.27 | $1.61 | ||
| Q1 25 | $1.19 | $1.41 | ||
| Q4 24 | $1.23 | $1.29 | ||
| Q3 24 | $1.43 | $1.50 | ||
| Q2 24 | $1.48 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $288.1M | — |
| Total DebtLower is stronger | $40.0M | — |
| Stockholders' EquityBook value | $4.4B | — |
| Total Assets | $5.7B | — |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $288.1M | — | ||
| Q4 25 | $120.1M | — | ||
| Q3 25 | $46.6M | $2.1B | ||
| Q2 25 | $24.1M | $1.4B | ||
| Q1 25 | $97.2M | $1.7B | ||
| Q4 24 | $108.7M | $2.0B | ||
| Q3 24 | $74.2M | $1.7B | ||
| Q2 24 | $104.6M | $1.6B |
| Q1 26 | $40.0M | — | ||
| Q4 25 | $20.0M | — | ||
| Q3 25 | $65.0M | — | ||
| Q2 25 | $150.0M | — | ||
| Q1 25 | $40.0M | — | ||
| Q4 24 | $40.0M | — | ||
| Q3 24 | $40.0M | — | ||
| Q2 24 | $40.0M | — |
| Q1 26 | $4.4B | — | ||
| Q4 25 | $4.3B | $3.3B | ||
| Q3 25 | $4.3B | $5.4B | ||
| Q2 25 | $4.2B | $5.0B | ||
| Q1 25 | $4.2B | $4.7B | ||
| Q4 24 | $4.2B | $4.8B | ||
| Q3 24 | $4.2B | $5.2B | ||
| Q2 24 | $4.1B | $5.0B |
| Q1 26 | $5.7B | — | ||
| Q4 25 | $5.5B | $15.5B | ||
| Q3 25 | $5.5B | $15.2B | ||
| Q2 25 | $5.6B | $14.5B | ||
| Q1 25 | $5.5B | $14.1B | ||
| Q4 24 | $5.5B | $14.2B | ||
| Q3 24 | $5.4B | $14.4B | ||
| Q2 24 | $5.3B | $14.2B |
| Q1 26 | 0.01× | — | ||
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.02× | — | ||
| Q2 25 | 0.04× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.01× | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.01× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ODFL
Segment breakdown not available.
ZTS
| Companion Animal | $1.5B | 67% |
| Livestock | $720.0M | 32% |
| Contract Manufacturing & Human Health | $23.0M | 1% |
